RENOWN NEWSROOM

Renown Medical Group is thrilled to welcome two distinguished breast surgical oncologists, Colleen O'Kelly-Priddy, MD and Michelle K. Chu, MD to the team. These highly skilled breast surgeons will solely focus on providing breast care and therefore play a pivotal role in Renown Health’s William N. Pennington Cancer Institute’s commitment to provide subspecialized care to the people living in our community and beyond. Dr. Colleen O'Kelly-Priddy is a fellowship-trained, board-certified breast surgical oncologist with an impressive background in breast cancer surgery. Dr. Priddy was born at Washoe Medical Center (which later became Renown Regional Medical Center) and grew up in Susanville, CA before attending Stanford University for her undergraduate studies. She is a graduate of the University of Nevada, Reno School of Medicine. "I am thrilled to return to Reno to help increase access to world-class surgical breast cancer care,” said Dr. Priddy. “My focus is to provide exceptional care, particularly for young people with breast cancer. I am excited to continue my mission here in northern Nevada." Dr. Michelle K. Chu, a board-certified general surgeon, brings her extensive experience in advanced breast cancer treatment to the Renown team. Dr. Chu received her undergraduate degree from the University of Pennsylvania and her medical degree from Western Reserve School of Medicine in Cleveland, OH. Dr. Chu specializes in oncoplastic breast conserving surgery and nipple sparing mastectomies. "I believe in tailoring treatment options to each patient's unique needs,” Dr. Chu said. “Whether it's preserving the natural shape of the breast or supporting the 'Going Flat' movement, our team strives to provide the best possible outcome for every patient." The newest addition to the William N. Pennington Cancer Institute, Renown Breast Surgery Care provides comprehensive breast surgery care at 1500 E. 2nd Street in Reno, adjacent to the Renown Regional Medical Center campus. "Breast cancer accounts for approximately 20% of newly diagnosed cancer cases in Washoe County, with roughly 520 new cases annually, establishing it as the most prevalent cancer type within our community,” says Brian Erling, MD, MBA, President & CEO, Renown Health. “We are proud, as the community’s largest not-for-profit healthcare system, to invest in cancer prevention and early diagnoses, including mammography screening and genetic research. For those diagnosed with breast cancer, Renown now offers two superb breast surgeons specializing in breast preservation surgery, and a breast surgery center providing comprehensive, compassionate care. Our goal is to save women’s lives, save families and ensure better care and better outcomes. This is a major step forward for women’s healthcare and our community.” As part of this expansion, Renown is assuming operations of Reno Surgical Advocates, a respected private practice in Reno. "Access to expert breast cancer care close to home is crucial, and our dedicated team at Renown Breast Surgery Care will work tirelessly to provide the highest level of care to patients while working closely with our other cancer specialists," said Max Coppes, MD, PhD, MBA, Director, William N. Pennington Institute for Cancer. “With the exceptional expertise of Dr. Colleen O'Kelly-Priddy and Dr. Michelle K. Chu, coupled with our state-of-the-art facility; Renown Health is a true partner in the fight against breast cancer in northern Nevada.” "People are increasingly relocating to northern Nevada, and in fact, Washoe County experienced a 2.1% population growth from April 2020 to July 2022. Consequently, although northern Nevada does not exhibit an above-average cancer rate, we are observing a rise in cases at our facilities," said Dr. Lee Schwartzberg, MD, FACP, Section Chief of Medical Oncology at the William N. Pennington Cancer Institute. "Renown Health is positioned to meet this growing demand, and we take pride in consistently adding nationally renowned healthcare providers to our team to save the lives of women in northern Nevada.     About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health.

Read More About Saving More Lives; Renown Expands Breast Cancer Care, Adding Two Best-In-Class Breast Surgeons

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

Read More About Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)